Chemed CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
CHE
Chemed CORPChemed Corporation reported Q2 2026 results with an 8.8% increase in consolidated service revenues and sales, driven by strong performance in its VITAS hospice care segment.
NYSE
CHE
Chemed CORPChemed Corporation's Q1 2026 filing reveals a 1.6% increase in consolidated revenue driven by VITAS, while Roto-Rooter experienced a slight decline, alongside significant stock repurchases.
NYSE
CHE
Chemed CORPChemed Corporation reported a decline in net income and diluted EPS for Q3 and the first nine months of 2025, despite revenue growth, driven by increased operating expenses and a new cybersecurity incident at its VITAS segment.
NYSE
CHE
Chemed CORPChemed Corporation experienced a decline in net income and EPS for Q2 2025 despite revenue growth, primarily due to a significant increase in Medicare Cap liability and higher casualty insurance expenses, alongside a notable executive departure.
NYSE
CHE
Chemed CORPChemed Corporation's Q1 2025 shows revenue and earnings growth, fueled by VITAS Healthcare and Roto-Rooter.
NYSE
CHE
Chemed CORPChemed Corporation's third-quarter results show strong growth in its VITAS hospice segment, which was partially offset by a decline in Roto-Rooter's revenue.
NYSE
CHE
Chemed CORP10-Q: Chemed Corporation Reports Strong Q2 Earnings Driven by VITAS Growth, Roto-Rooter Revenue Declines
Chemed Corporation's second-quarter earnings were bolstered by a significant increase in VITAS Healthcare's revenue, while Roto-Rooter experienced a decline in service revenue.
NYSE
CHE
Chemed CORPChemed Corporation's first quarter 2024 results show a revenue increase driven by VITAS Healthcare, despite a decrease in Roto-Rooter revenue.